Search

Displaying results 2721 - 2730 of 4690 in total
  1. Drug

    Dofetilide

    go.drugbank.com/drugs/DB00204
    ApprovedInvestigational

    Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation

  2. Drug

    Raxibacumab

    go.drugbank.com/drugs/DB08902
    ApprovedInvestigational

    Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.

  3. Drug

    Doxofylline

    go.drugbank.com/drugs/DB09273
    Investigational

    As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. … The anti-asthmatic effects of doxophylline are mediated by other mechanisms, primarily through inhibiting the activities of the phosphodiesterase (PDE) enzyme.

  4. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market.

  5. Drug

    Probenecid

    go.drugbank.com/drugs/DB01032
    ApprovedInvestigational

    The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubu...

  6. Drug

    Peppermint oil

    go.drugbank.com/drugs/DB11198
    ApprovedInvestigational

    Due to its effectiveness in relaxing GI smooth muscle but ability to induce gastroesophageal reflux, enteric-coated formulations of peppermint oil has been established which bypass the upper GI tract unmetabolized

  7. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy.

  8. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.

  9. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.

  10. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    The bacille Calmette-Guérin (BCG) vaccine protects against severe extrapulmonary forms of tuberculosis (TB) but does not adequately protect against pulmonary TB -- the most prevalent form of TB. … By reducing urease C, phagosome acidification can occur, promoting phagolysosome fusion while also providing the optimal low pH for listeriolysin O stability.